Comorbidity Factors Identified for Exacerbation-Prone Asthma

Share this content:
Comorbidity Factors Identified for Exacerbation-Prone Asthma
Comorbidity Factors Identified for Exacerbation-Prone Asthma

THURSDAY, Sept. 1, 2016 (HealthDay News) -- Factors that are associated with exacerbation-prone asthma (EPA) have been identified, with blood eosinophils, body mass index, and bronchodilator responsiveness associated with exacerbation frequency, according to a study published online Aug. 24 in the American Journal of Respiratory and Critical Care Medicine.

Loren C. Denlinger, M.D., Ph.D., from the University of Wisconsin in Madison, and colleagues examined the clinical, physiological, inflammatory, and comorbidity factors associated with EPA. Patients were classified by the number of exacerbations in the previous year.

The researchers found that 41 percent of the 709 subjects in the National Heart, Lung, and Blood Institute Severe Asthma Research Program (SARP)-3 cohort had no exacerbations and 24 percent were exacerbation prone in the previous year. In SARP-3, factors normally associated with severity (asthma duration, age, sex, race, and socioeconomic status) were not associated with exacerbation frequency; bronchodilator responsiveness differentiated exacerbation proneness from asthma severity. There were positive associations for blood eosinophils, body mass index, and bronchodilator responsiveness with exacerbation frequency in the SARP-3 multivariable model. Even after adjustment for multiple factors, chronic sinusitis and gastroesophageal reflux were also associated with exacerbation frequency. In the SARP 1 + 2 multivariable model, these effects were replicated.

"EPA may be a distinct susceptibility phenotype with implications for the targeting of exacerbation prevention strategies," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »